|Articles|November 1, 2011

Pharmaceutical Executive

  • Pharmaceutical Executive-11-01-2011
  • Volume 0
  • Issue 0

Euroservice

Know your strengths, then expand

Igor Kouznetsov founded Euroservice in 1996. From a staff of six, the company has grown to become the ninth-largest importing distributor on the Russian pharmaceutical market (Pharmexpert, 2010). To explain this success, Kouznetsov constantly cites "specialization"—from its inception, Euroservice has been focused on the hospital segment.

Igor Kouznetsov, Euroservice General Director

However, today, Euroservice is more than a distributor. Kouznetsov explains, "Over time, we began to think about the evolution of our service offering, and decided that beyond distribution, we could offer additional services to foreign companies. Euroservice was the first hospital products distributor to sign a contract with a foreign producer for product marketing." Euroservice has successfully marketed drugs for a number of international players, and is most interested in partnering with high-technology small businesses.

Kouznetsov invites foreign businesses to Russia. "We are open to collaboration," Kouznetsov says. "For like companies, we are strong partners both in marketing and distribution. We want to take products from the registration stage through the marketing stage, and see ourselves as a full-service enterprise."

Articles in this issue

almost 15 years ago

Plant Management

almost 15 years ago

The Road from No. 20

almost 15 years ago

Five Years

almost 15 years ago

Spotlight on OTCs

almost 15 years ago

Invar

almost 15 years ago

The Drug Shortages Struggle

almost 15 years ago

Pharma's Visit to the Plastic Surgeon

almost 15 years ago

The Pharma Revolution Recalibrated

Related to this article

Pharmaceutical Executive Daily
The FDA approves Roche’s Tecentriq for a subset of colon cancer patients, TRexBio and Retension Pharmaceuticals price new IPOs, and a Pharmaceutical Executive feature examines what it takes to turn precision medicine’s biological gains into deliverable therapies.
Naoki Okamura: Post-Patent Plan and Purpose
Astellas CEO Naoki Okamura is putting a “patient axis” operating model, a broader portfolio of strategic brands and a new generation of science to work in the company’s bid to return to record growth.